1994
1994
Veristat was founded by John and Barbara Balser, marking the start of a Clinical Research Organization (CRO) dedicated to solving the most difficult scientific and clinical challenges.
2007
Veristat becomes a registered CDISC solutions provider, integral to our offering to ensure timely and compliant FDA submissions and reviews.
2007
2011
Veristat adds Clinical Operations Services, expanding our ability to conduct clinical trials with the highest levels of scientific excellence, efficiency and results.
2013
Patrick Flanagan joins as CEO to lead the company’s business strategy, organizational management and financial performance.
2013
2016
Veristat expands into Europe with the acquisition of Spero Oncology and launches our Strategic Consulting Group.
2018
Clinical Operations Services are strengthened with the acquisition of Topstone Clinical Research.
Regulatory Services are established, foundational to Veristat’s core service offering.
2018
2019
Operations expand into Asia with the opening of Veristat’s Taipei office.
The acquisition of Catalyst strengthens North American capabilities in Regulatory Affairs.
2020
Veristat’s acquisition of TCTC brings substantive capabilities and talent in Advanced Therapy solutions, furthering geographic reach into the UK and EU regions.
The acquisition of Certus PV advances Veristat’s commitment to patient safety by adding post-market pharmacovigilance services.
Enhances patient-centricity offering by launching a flexible virtual clinical trial solution.
2020
2021
Veristat’s impact in Biometrics and European Regulatory is enhanced with the acquisitions of SQN Clinical and DDR.
European footprint expands with the opening of our Barcelona office.
2022
The acquisition of SFL adds commercialization capabilities, expands our EU footprint and diversifies our client base.
Launches Strategic Resourcing/FSP solutions to build greater flexibility for sponsors.
Integrates Decentralized Clinical Trial (DCT) solutions into our clinical development full-service offerings
2022
2024
Ready to speak with the scientific-minded
experts who make the impossible possible?
Learn More with These Resources
Case Study
Flexibility Drives Progress in Rare Disease Gene Therapy Trial
Case Study
Supporting Global Approval of a First-in-ClassGene Therapy ...
Case Study
Efficient Regulatory Publishing for Large-Scale FDA Submission